MetaCap

Alzamend Neuro (ALZN) vs Processa Pharmaceuticals (PCSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Processa Pharmaceuticals is the larger company by market cap ($4.4 million vs $3.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALZN-43.37%PCSA+9.86%
+41%-3%-47%
Oct 7, 20261 yearNov 20, 2026
ALZN-42.10%PCSA+2.63%
+30%-8%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALZN versus PCSA key metrics
MetricALZNPCSA
Share price$0.7758$1.56
Market cap$3.74M$4.37M
1-day change-23.94%-7.69%
EPS (TTM)$-2.30$-68.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-13.56M
52-week high$2.54$8.88
52-week low$0.754$1.04
Distance from 52-week high-69.40%-82.43%
Analyst consensusnone—
Avg. price target upside+3251.38%—
Average volume70.27K79.50K
Shares outstanding4.83M2.80M
Employees412
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alzamend Neuro

ALZN stock →

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Processa Pharmaceuticals

PCSA stock →

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ALZN vs PCSA FAQ

Which is bigger, Alzamend Neuro or Processa Pharmaceuticals?

Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $4.37M compared with $3.74M for Alzamend Neuro (ALZN).

Are Alzamend Neuro and Processa Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons